ATE467623T1 - Diazepan-acetamidderivate als selektive 11-hsd1- hemmer - Google Patents

Diazepan-acetamidderivate als selektive 11-hsd1- hemmer

Info

Publication number
ATE467623T1
ATE467623T1 AT07818740T AT07818740T ATE467623T1 AT E467623 T1 ATE467623 T1 AT E467623T1 AT 07818740 T AT07818740 T AT 07818740T AT 07818740 T AT07818740 T AT 07818740T AT E467623 T1 ATE467623 T1 AT E467623T1
Authority
AT
Austria
Prior art keywords
diazepan
selective
acetamide derivatives
hsd1 inhibitors
hsd1
Prior art date
Application number
AT07818740T
Other languages
English (en)
Inventor
Denis Carniato
Caroline Leriche
Didier Roche
Christine Charon
Liliane Doare
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE467623T1 publication Critical patent/ATE467623T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
AT07818740T 2006-11-03 2007-10-05 Diazepan-acetamidderivate als selektive 11-hsd1- hemmer ATE467623T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06291704A EP1918285A1 (de) 2006-11-03 2006-11-03 Diazepanacetamidderivate als selektive 11B-HSD1 Inhibitoren
PCT/EP2007/008664 WO2008052638A1 (de) 2006-11-03 2007-10-05 DIAZEPANE-ACETAMIDE DERIVATIVES AS SELECTIVE 11β-HSD1 INHIBITORS

Publications (1)

Publication Number Publication Date
ATE467623T1 true ATE467623T1 (de) 2010-05-15

Family

ID=38462005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07818740T ATE467623T1 (de) 2006-11-03 2007-10-05 Diazepan-acetamidderivate als selektive 11-hsd1- hemmer

Country Status (16)

Country Link
US (2) US8242107B2 (de)
EP (2) EP1918285A1 (de)
JP (1) JP5538892B2 (de)
AR (1) AR063454A1 (de)
AT (1) ATE467623T1 (de)
AU (1) AU2007315307B2 (de)
CA (1) CA2668504C (de)
CY (1) CY1110928T1 (de)
DE (1) DE602007006535D1 (de)
DK (1) DK2078001T3 (de)
ES (1) ES2345296T3 (de)
IL (1) IL198462A (de)
PL (1) PL2078001T3 (de)
PT (1) PT2078001E (de)
SI (1) SI2078001T1 (de)
WO (1) WO2008052638A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152271B1 (de) 2007-06-08 2015-10-21 Janssen Pharmaceutica, N.V. Piperidin-/piperazinderivate
AU2008258487B2 (en) 2007-06-08 2012-11-15 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5579170B2 (ja) * 2008-06-05 2014-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｄｇａｔ阻害剤とｐｐａｒ作動薬を含有する薬剤組み合わせ物
EP2243479A3 (de) 2009-04-20 2011-01-19 Abbott Laboratories Neuartige Amid- und Amidinderivate und deren Verwendungen
ES2350077B1 (es) * 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2818463A1 (de) 2010-08-26 2014-12-31 Kowa Co., Ltd. Herstellungsverfahren für 1,4-diazepan derivate
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3235813A1 (de) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo-derivate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1087491A (ja) * 1996-07-26 1998-04-07 Asahi Chem Ind Co Ltd 転写調節因子阻害剤
CA2285705A1 (en) * 1997-04-14 1998-10-22 Cor Therapeutics, Inc. Selective factor xa inhibitors
EP0975625A1 (de) * 1997-04-14 2000-02-02 Cor Therapeutics, Inc. AUSWÄHLEND Xa KAKTOR INHIBITOREN
BR0315166A (pt) * 2002-10-11 2005-08-16 Astrazeneca Ab Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
EP1703908A4 (de) * 2003-12-22 2009-07-08 Amgen Inc Arylsulfonamidverbindungen und damit in bezug stehende verwendungen
CA2570637A1 (en) * 2004-06-24 2006-02-02 Wenqing Yao N-substituted piperidines and their use as pharmaceuticals
BRPI0609062A2 (pt) * 2005-03-03 2010-02-17 F. Hofmann-La Roche Ag composição farmacêutica, compostos, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de deidrogenase de hidroxiesteróide-11ß e utilização dos compostos

Also Published As

Publication number Publication date
DK2078001T3 (da) 2010-07-19
SI2078001T1 (sl) 2010-07-30
US8242107B2 (en) 2012-08-14
US20120283247A1 (en) 2012-11-08
EP2078001A1 (de) 2009-07-15
AU2007315307B2 (en) 2013-05-09
US20100069365A1 (en) 2010-03-18
WO2008052638A1 (de) 2008-05-08
EP2078001B1 (de) 2010-05-12
ES2345296T3 (es) 2010-09-20
PT2078001E (pt) 2010-08-18
IL198462A (en) 2014-12-31
CY1110928T1 (el) 2015-06-10
US8586577B2 (en) 2013-11-19
IL198462A0 (en) 2010-02-17
EP2078001B8 (de) 2010-12-15
CA2668504A1 (en) 2008-05-08
JP2010508312A (ja) 2010-03-18
AR063454A1 (es) 2009-01-28
DE602007006535D1 (de) 2010-06-24
EP1918285A1 (de) 2008-05-07
PL2078001T3 (pl) 2010-11-30
JP5538892B2 (ja) 2014-07-02
AU2007315307A1 (en) 2008-05-08
CA2668504C (en) 2015-06-30

Similar Documents

Publication Publication Date Title
ATE467623T1 (de) Diazepan-acetamidderivate als selektive 11-hsd1- hemmer
DK2016080T3 (da) Dihydropyrazolopyrimidinon-derivater
ATE483711T1 (de) Spiroindolinonderivate
ATE469905T1 (de) Pyridopyrimidinonderivate
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
ATE512135T1 (de) Spiroindolinonderivate
ATE510825T1 (de) Acylaminopyrazole als fgfr-inhibitoren
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2035394T3 (da) 2-pyrazincarboxamidderivater
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE485268T1 (de) Pyrrolidin-derivate als erk-hemmer
ATE549340T1 (de) Spiroindolinon-derivate als mdm2-p53 inhibitoren
CR10478A (es) Amino-piperidine derivatives as cetp inhibitors
DK2094263T3 (da) 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE475649T1 (de) Pyridincarboxamide als 11-beta-hsd1-inhibitoren
ATE478064T1 (de) Als pi-3-kinaseinhibitoren verwendete pyrimidinderivate
ATE493411T1 (de) Pyrroloä2, 3-büpyridin-4-yl- benzolsulfonamidverbindungen als ikk2-hemmer
ATE506358T1 (de) 2-benzylpyridazinonderivate als met-kinasehemmer
EP2072519A4 (de) Diarylketiminderivat
NO20085127L (no) Leptomycinderivater
ATE545417T1 (de) Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
CR10879A (es) Cyclized derivatives as eg-5 inhibitors
ATE544764T1 (de) 5-hydroxymethyloxazolidin-2-onderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2078001

Country of ref document: EP